ES2138740T3 - Modificacion de toxinas de clostridium utilizadas como proteinas de transporte. - Google Patents

Modificacion de toxinas de clostridium utilizadas como proteinas de transporte.

Info

Publication number
ES2138740T3
ES2138740T3 ES95921007T ES95921007T ES2138740T3 ES 2138740 T3 ES2138740 T3 ES 2138740T3 ES 95921007 T ES95921007 T ES 95921007T ES 95921007 T ES95921007 T ES 95921007T ES 2138740 T3 ES2138740 T3 ES 2138740T3
Authority
ES
Spain
Prior art keywords
modification
transport proteins
toxin
toxins used
clostridium toxins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95921007T
Other languages
English (en)
Inventor
James Oliver Dolly
Kei Roger Aoki
Larry Allen Wheeler
Michael Elwood Garst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9410870A external-priority patent/GB9410870D0/en
Priority claimed from GB9410871A external-priority patent/GB9410871D0/en
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2138740T3 publication Critical patent/ES2138740T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE FACILITA UN CONJUGADO QUIMICO PARA TRATAR UNA ENFERMEDAD RELACIONADA CON LAS CELULAS NERVIOSAS. ESTE CONJUGADO INCLUYE UNA TOXINA CLOSTRIDIAL ACTIVA O INACTIVA QUE TIENE ESPECIFICIDAD PARA UNA CELULA NERVIOSA DE DESTINO. LA TOXINA SE CONJUGA EN UN MEDICAMENTO U OTRA MOLECULA BIOACTIVA SIN AFECTAR A LA CAPACIDAD DE LA TOXINA PARA ENTRAR EN LA CELULA NERVIOSA DE DESTINO.
ES95921007T 1994-05-31 1995-05-31 Modificacion de toxinas de clostridium utilizadas como proteinas de transporte. Expired - Lifetime ES2138740T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9410870A GB9410870D0 (en) 1994-05-31 1994-05-31 Modification of botulinum toxins for use as transport proteins
GB9410871A GB9410871D0 (en) 1994-05-31 1994-05-31 Modification of tetanus toxin for use as a transport protein

Publications (1)

Publication Number Publication Date
ES2138740T3 true ES2138740T3 (es) 2000-01-16

Family

ID=26304971

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95921007T Expired - Lifetime ES2138740T3 (es) 1994-05-31 1995-05-31 Modificacion de toxinas de clostridium utilizadas como proteinas de transporte.

Country Status (9)

Country Link
US (1) US6203794B1 (es)
EP (1) EP0760681B1 (es)
JP (1) JP3523879B2 (es)
AU (1) AU695623B2 (es)
CA (1) CA2191754C (es)
DE (1) DE69511860T2 (es)
DK (1) DK0760681T3 (es)
ES (1) ES2138740T3 (es)
WO (1) WO1995032738A1 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US7227010B2 (en) 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
GB9524807D0 (en) * 1995-12-05 1996-02-07 Smithkline Beecham Plc Novel compounds
US6169074B1 (en) 1996-03-18 2001-01-02 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US6051239A (en) * 1997-10-20 2000-04-18 Thomas Jefferson University Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
WO1999037326A1 (en) * 1998-01-26 1999-07-29 University Of Massachusetts Biologically active hemagglutinin from type a clostridium botulinum and methods of use
DE19856052A1 (de) * 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
EP1210444A2 (en) * 1999-08-20 2002-06-05 Imperial College Innovations Limited Isoforms of snare molecules and the uses thereof in modulation of cellular exocytosis
EP2267008B1 (en) * 1999-08-25 2014-07-02 Allergan, Inc. Activatable recombinant neurotoxins
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
DE60130266D1 (de) * 2000-11-06 2007-10-11 Us Army Med Res Mat Command Rekombinante leichte kette des botolinum neurotoxins and fusionsproteine davon zur verwendung in forschung und klinischer therapie
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US6787517B1 (en) 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
WO2002086131A1 (fr) * 2001-04-09 2002-10-31 Gencom Corporation Unite de regulation de l'expression genetique et utilisation de cette unite
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
GB0112687D0 (en) * 2001-05-24 2001-07-18 Microbiological Res Authority Pharmaceutical use of secreted bacterial effector proteins
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040013687A1 (en) * 2002-05-31 2004-01-22 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
AU2003272800A1 (en) 2002-10-01 2004-04-23 University Of Maryland Methods for identifying inhibitors of botulinum neurotoxins
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
NZ540425A (en) * 2002-12-20 2009-03-31 Botulinum Toxin Res Ass Inc Pharmaceutical botulinum toxin compositions
JP2007070225A (ja) * 2003-07-25 2007-03-22 Yukako Fujinaga クロストリジウム属菌由来成分を含む医薬製剤
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
JP4994241B2 (ja) * 2004-11-22 2012-08-08 ニューヨーク・ユニバーシティ 遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
DK2154151T3 (da) * 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
AU2007347781B2 (en) 2006-07-11 2013-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
US8586081B2 (en) * 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
WO2009131435A1 (en) * 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Linker containing bungarotoxin and a binding peptide
CA2745657C (en) 2008-12-04 2022-06-21 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
WO2010085473A1 (en) * 2009-01-20 2010-07-29 Trustees Of Tufts College Methods for the delivery of toxins or enzymatically active portions thereof
EP2218783A1 (en) 2009-02-05 2010-08-18 Merz Pharma GmbH & Co. KGaA Novel method for the manufacturing of neurotoxins
US20120244188A1 (en) * 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
EP2793934B1 (en) 2011-12-23 2017-08-23 Merz Pharma GmbH & Co. KGaA Novel method for the manufacturing of di-chain proteins for use in humans
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
MX359480B (es) 2012-05-30 2018-09-28 President And Fellows Of Harvard College Star Neurotoxina botulínica diseñada.
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
WO2014117148A1 (en) 2013-01-28 2014-07-31 New York University Treatment methods using atoxic neurotoxin derivatives
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
EP3113792B1 (en) 2014-03-05 2018-12-05 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with increased duration of effect
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11897921B2 (en) 2014-12-09 2024-02-13 New York University Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
KR102514666B1 (ko) 2014-12-19 2023-03-27 메르츠 파마 게엠베하 운트 코. 카가아 세포에서 BoNT/E의 생물학적 활성의 결정을 위한 수단 및 방법
RU2746736C2 (ru) 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
ES2929347T3 (es) 2016-01-20 2022-11-28 Merz Pharma Gmbh & Co Kgaa Nuevas neurotoxinas clostridiales recombinantes con aumento de la duración del efecto
MX395130B (es) 2016-03-02 2025-03-24 Merz Pharma Gmbh & Co Kgaa Composicion que comprende toxina botulinica
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
AU2017345560C1 (en) 2016-10-20 2025-04-17 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
EP3333179A1 (en) 2016-12-07 2018-06-13 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with accelarated onset of effect
EP3335719A1 (en) 2016-12-14 2018-06-20 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with a stabilized light chain
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
WO2019081022A1 (en) 2017-10-26 2019-05-02 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM NEUROTOXINS WITH INCREASED DURATION
EP3713595A1 (en) 2017-11-22 2020-09-30 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
WO2023105289A1 (en) 2021-12-06 2023-06-15 Dublin City University Methods and compositions for the treatment of pain

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4594336A (en) 1982-09-28 1986-06-10 Institut Pasteur Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5204097A (en) * 1986-07-06 1993-04-20 Yeda Research And Development Company Limited Shiga toxin B chain polypeptides and vaccine thereto
IL79346A0 (en) 1986-07-06 1986-10-31 Yeda Res & Dev Shiga vaccine
US5719267A (en) * 1989-10-31 1998-02-17 Ophidian Pharmaceuticals Inc. Clostridial toxin disease therapy
US5196193A (en) * 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
US5599539A (en) * 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
EP0625910B1 (en) * 1992-02-11 2003-07-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
EP0654040A1 (en) * 1992-06-23 1995-05-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
WO1994000487A1 (en) * 1992-06-30 1994-01-06 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Peptide which produces protective immunity against tetanus
GB9305735D0 (en) * 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5693476A (en) * 1995-02-24 1997-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of screening for compounds capable of modulating vesicular release
US5650280A (en) * 1995-03-23 1997-07-22 Incyte Pharmaceuticals, Inc. Cellubrevin homolog
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US5965699A (en) * 1996-11-06 1999-10-12 The United States Of America As Represented By The Secretary Of The Army Assay for the proteolytic activity of serotype a from clostridium botulinum
US5955368A (en) * 1998-04-06 1999-09-21 Wisconsin Alumni Research Foundation Expression system for clostridium species

Also Published As

Publication number Publication date
DE69511860T2 (de) 2000-02-10
DE69511860D1 (de) 1999-10-07
EP0760681B1 (en) 1999-09-01
US6203794B1 (en) 2001-03-20
JP3523879B2 (ja) 2004-04-26
AU2622295A (en) 1995-12-21
JPH10500988A (ja) 1998-01-27
EP0760681A1 (en) 1997-03-12
DK0760681T3 (da) 2000-03-27
CA2191754A1 (en) 1995-12-07
CA2191754C (en) 2000-12-12
AU695623B2 (en) 1998-08-20
WO1995032738A1 (en) 1995-12-07

Similar Documents

Publication Publication Date Title
ES2130420T3 (es) Preparado transdermico de sustancia activa.
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
CA2191754A1 (en) Modification of Clostridial Toxins for Use as Transport Proteins
GB9721189D0 (en) Analgesic conjugates
DE69637147D1 (de) Transportproteine und deren verwendungen
BR9509269A (pt) Processo para tratar diabetes
ES2088425T3 (es) Metodo de produccion de xilitol a partir de mezclas que contienen xilosa.
ATE261494T1 (de) Konstrukte zur verabreichung von therapeutischen wirkstoffen an die neuronzellen
GEP20043171B (en) Skin with a Minimal Systemic Effect
ES2046176T3 (es) Composicion farmaceutica que contiene una asociacion de colageno y de un principio activo antiseptico y/o antiinflamatorio y su procedimiento de fabricacion.
ES2014429B3 (es) Nuevas 4-triazol-4,3-a 1,4-benzodiazepinas, procedimiento para su preparacion, su aplicacion como medicamentos y preparaciones que las contienen.
ES2034926T1 (es) Composiciones farmaceuticas orales liquidas con actividad anti-inflamatoria.
ES2134924T3 (es) Acidos sulfonilalcanoilamino-hidroxietilamino-sulfamicos utiles como inhibidores de proteasas retrovirales.
ES2148310T3 (es) Procedimiento para fabricar conjugados de lipidos.
TR199903192T2 (xx) Eritropoetin, de�i�tirilmi� hemoglobin i�eren farmasotik kombine m�stahzarlar.
PT95697A (pt) Processo para a preparacao de composicoes farmaceuticas contendo substancias antiandrogenicamente activas
MX9306419A (es) Bifenilos trisustituidos, procedimiento para su obtencion y medicamentos que los contienen.
TR200001486T2 (tr) Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
ES2156220T3 (es) Preparacion transdermica que contiene un metabolito de loratidina con accion antihistaminica.
AR011238A1 (es) Composicion que consiste esencialmente de toxina gbs (bacterias streptococcus beta-hemoliticos del grupo b), composicion farmaceutica, metodode purificacion de dicha toxina, toxina obtenida mediante dicho metodo y uso de dicha toxina para preparar composiciones farmaceuticas
DE58906338D1 (de) Kombination von Angiotensin-Converting-Enzyme-Hemmern mit Kaliumkanal-Modulatoren sowie deren Verwendung in Arzneimitteln.
WO2000033880A3 (de) Konjugat zur anreicherung in neuronalen zellen
ES2169915T3 (es) Composicion utilizable en los ambitos farmaceutico, dietetico y cosmetico.
CO4410254A1 (es) Procedimiento para introducir material extrano en celulas eucarioticas superiores

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 760681

Country of ref document: ES